methylphenidate hydrochloride (la)- methylphenidate hydrochloride capsule, extended release
teva pharmaceuticals usa, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 20 mg - methylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd), in pediatric patients 6 to 12 years of age [see clinical studies (14)] . - hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride extended-release capsules. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate [ s ee adverse reactions (6.1)]. - concomitant treatment with monoamine oxidase inhibitors (maois), or within 14 days following discontinuation of treatment with an maoi, because of the risk of hypertensive crises [ see drug interactions (7.1)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including methylphenidate hydrochloride extended-release capsules during pregnancy. healthcare providers are encouraged to register patients by calling the national pregna
methylphenidate hydrochloride tablet methylphenidate hydrochloride tablet, extended release
specgx llc - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg - methylphenidate hydrochloride tablets and methylphenidate hydrochloride extended-release tablets are indicated for the treatment of: - attention deficit hyperactivity disorders (adhd) in pediatric patients 6 years and older and adults - narcolepsy - hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride tablets or methylphenidate hydrochloride extended-release tablets. hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate [see adverse reactions (6)] . - concomitant treatment with monoamine oxidase inhibitors (maois), or within 14 days following discontinuation of treatment with an maoi, because of the risk of hypertensive crises [see drug interactions (7.1)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including methylphenidate hydrochloride tablets and methylphenidate hydrochloride extended-release
selegiline 5mg tablets
a a h pharmaceuticals ltd - selegiline hydrochloride - oral tablet - 5mg
selegiline 5mg tablets
actavis uk ltd - selegiline hydrochloride - oral tablet - 5mg
selegiline 5mg tablets
teva uk ltd - selegiline hydrochloride - oral tablet - 5mg
selegiline 5mg tablets
the boots company plc - selegiline hydrochloride - oral tablet - 5mg
selegiline 5mg tablets
ivax pharmaceuticals uk ltd - selegiline hydrochloride - oral tablet - 5mg
selegiline 5mg tablets
kent pharma (uk) ltd - selegiline hydrochloride - oral tablet - 5mg
selegiline 5mg tablets
sterwin medicines - selegiline hydrochloride - oral tablet - 5mg
selegiline 5mg tablets
alliance healthcare (distribution) ltd - selegiline hydrochloride - oral tablet - 5mg